These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16406508)

  • 1. The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress.
    Nishitsuji K; To H; Shimizu T; Yanase Y; Yamada T; Hara C; Mine K; Higuchi S
    Eur Neuropsychopharmacol; 2006 Jul; 16(5):376-82. PubMed ID: 16406508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear.
    Nishikawa H; Inoue T; Masui T; Izumi T; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):926-31. PubMed ID: 17376576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interaction between tandospirone and fluvoxamine in the rat contextual conditioned fear stress model and its functional consequence: Involvement of cytochrome P450 3A4.
    Nishikawa H; Inoue T; Masui T; Izumi T; Nakagawa S; Koyama T
    Psychiatry Clin Neurosci; 2008 Oct; 62(5):591-6. PubMed ID: 18950380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine.
    Miller LG; Thompson ML; Byrnes JJ; Greenblatt DJ; Shemer A
    J Clin Psychopharmacol; 1992 Oct; 12(5):341-5. PubMed ID: 1362206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans.
    Evans SM; Troisi JR; Griffiths RR
    J Pharmacol Exp Ther; 1994 Nov; 271(2):683-94. PubMed ID: 7965783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rat brain concentrations of monoamines and their metabolites after chronic administration of diazepam and tandospirone].
    Nishikouri Y; Ikeda R; Kubodera K; Taniguchi M; Hikiba S; Kondoh M; Ikeuchi N; Shimizu M; Miura S
    Yakubutsu Seishin Kodo; 1992 Feb; 12(1):9-15. PubMed ID: 1357841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new approach to innovating selective anxiolytics: pharmacological profile of a novel 5-HT1A agonist (tandospirone)].
    Sasa M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1997 Apr; 17(2):53-9. PubMed ID: 9201724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effects of tandospirone and selective serotonin reuptake inhibitors on the contextual conditioned fear stress response in rats.
    Nishikawa H; Inoue T; Izumi T; Koyama T
    Eur Neuropsychopharmacol; 2007 Oct; 17(10):643-50. PubMed ID: 17368862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT1A receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT1A receptors in the hippocampus and amygdala.
    Li X; Inoue T; Abekawa T; Weng S; Nakagawa S; Izumi T; Koyama T
    Eur J Pharmacol; 2006 Feb; 532(1-2):74-80. PubMed ID: 16460727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic treatment with tandospirone, a serotonin 1A receptor partial agonist, inhibits psychosocial stress-induced changes in hippocampal neurogenesis and behavior.
    Murata Y; Yanagihara Y; Mori M; Mine K; Enjoji M
    J Affect Disord; 2015 Jul; 180():1-9. PubMed ID: 25879718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of the serotonergic anxiolytic tandospirone (SM-3997).
    Seymour PA; Mena EE; McLean S; Heym J
    Prog Clin Biol Res; 1990; 361():453-60. PubMed ID: 1981263
    [No Abstract]   [Full Text] [Related]  

  • 12. Facilitation of fear extinction by the 5-HT(1A) receptor agonist tandospirone: possible involvement of dopaminergic modulation.
    Saito Y; Matsumoto M; Yanagawa Y; Hiraide S; Inoue S; Kubo Y; Shimamura K; Togashi H
    Synapse; 2013 Apr; 67(4):161-70. PubMed ID: 23152167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the anxiolytic-like effects of fluvoxamine, milnacipran and risperidone in mice using the conditioned fear stress paradigm.
    Miyamoto J; Tsuji M; Takeda H; Ohzeki M; Nawa H; Matsumiya T
    Eur J Pharmacol; 2004 Nov; 504(1-2):97-103. PubMed ID: 15507225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early postnatal stress alters the extinction of context-dependent conditioned fear in adult rats.
    Matsumoto M; Togashi H; Konno K; Koseki H; Hirata R; Izumi T; Yamaguchi T; Yoshioka M
    Pharmacol Biochem Behav; 2008 May; 89(3):247-52. PubMed ID: 18262260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tandospirone, a 5-HT1A receptor-related anxiolytic, on daytime sleepiness and psychomotor functions: a comparative double-blind study with diazepam.
    Suzuki M; Uchiumi M; Murasaki M
    Yakubutsu Seishin Kodo; 1993 Aug; 13(4):213-24. PubMed ID: 7901952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of MS-153 on the acquisition and expression of conditioned fear in rats.
    Li X; Inouei T; Abekawai T; YiRui F; Koyama T
    Eur J Pharmacol; 2004 Nov; 505(1-3):145-9. PubMed ID: 15556147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats.
    Kasahara K; Hashimoto S; Hattori T; Kawasaki K; Tsujita R; Nakazono O; Takao K; Kawakubo H; Nagatani T
    J Pharmacol Sci; 2015 Jan; 127(1):109-16. PubMed ID: 25704026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action.
    Vaidya AH; Rosenthal DI; Lang W; Crooke JJ; Benjamin D; Ilyin SE; Reitz AB
    Methods Find Exp Clin Pharmacol; 2005 May; 27(4):245-55. PubMed ID: 16082425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticonflict action of tandospirone in a modified Geller-Seifter conflict test in rats.
    Shimizu H; Kumasaka Y; Tanaka H; Hirose A; Nakamura M
    Jpn J Pharmacol; 1992 Mar; 58(3):283-9. PubMed ID: 1355147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158.
    Tsutsumi T; Akiyoshi J; Isogawa K; Kohno Y; Hikichi T; Nagayama H
    Neuropeptides; 1999 Dec; 33(6):483-6. PubMed ID: 10657528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.